Cargando…
Review of the clinical evidence for interferon β 1a (Rebif(®)) in the treatment of multiple sclerosis
Interferon (INF) β 1a 22 or 44 μg (Rebif(®)) administered s.c. 3 times a week (t.i.w) is a well established immunomodulating treatment for relapsing remitting multiple sclerosis (RRMS). This review focuses on its mechanisms of action, evidence of efficacy, safety, and tolerability. Several pharmacod...
Autores principales: | Manfredonia, Francesco, Pasquali, Livia, Dardano, Angela, Iudice, Alfonso, Murri, Luigi, Monzani, Fabio |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518386/ https://www.ncbi.nlm.nih.gov/pubmed/18728744 |
Ejemplares similares
-
Antibodies to Interferon beta in Patients with Multiple Sclerosis Receiving CinnoVex, Rebif, and Betaferon
por: Zare, Nasrin, et al.
Publicado: (2013) -
Glatiramer acetate in the treatment of multiple sclerosis
por: Tselis, Alex, et al.
Publicado: (2007) -
The adoption of nintedanib in systemic sclerosis: the SENSCIS study
por: Bruni, Teresa, et al.
Publicado: (2020) -
The role of glatiramer acetate in the early treatment of multiple sclerosis
por: Brandes, David W
Publicado: (2010) -
Riluzole 5 mg/mL oral suspension: for optimized drug delivery in amyotrophic lateral sclerosis
por: Dyer, Ann Margaret, et al.
Publicado: (2016)